Sentences with phrase «direct cell therapy product»

Not exact matches

ViaCyte's PEC - Encap ™ (also known as VC - 01) product candidate delivers the same cell therapy as PEC - Direct but uses a proprietary device called the Encaptra ® Cell Delivery System that is designed to protect the cells from the patient's immune syscell therapy as PEC - Direct but uses a proprietary device called the Encaptra ® Cell Delivery System that is designed to protect the cells from the patient's immune sysCell Delivery System that is designed to protect the cells from the patient's immune system.

The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

Preparation and global prosecution of patent applications directed to diagnostic and therapeutic products including antibodies, gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.